DORVAL, QC, June 26, 2014 /CNW Telbec/ - Warnex Inc. (TSXV: WNX.H) ("Warnex") is pleased to announce that, at an annual and special meeting of its
shareholders (the "Meeting") held earlier today, its shareholders approved the terms of its
previously announced amalgamation (the "Amalgamation") with a wholly-owned subsidiary of Diagnos Inc. ("Diagnos") (TSX-V: ADK). The Amalgamation was approved by 99.95% of Warnex
shareholders voting in person or by proxy at the Meeting.
Closing of the Amalgamation is expected to occur on or about July 8,
Upon closing of the Amalgamation, shareholders of Warnex will receive
one common share of Diagnos (a "Diagnos Share") for each common share of Warnex (a "Warnex Share") held. Each shareholder of Warnex and Diagnos will, following closing
of the Amalgamation, be entitled to receive one half warrant (a "Warrant") to purchase one Diagnos Share for each Warnex Share or Diagnos Share
held. Each whole Warrant will be exercisable at a price of $0.10 per
share for a period of twelve months following the closing of the
It is also expected that, following the closing of the Amalgamation, the
Warnex Shares will be delisted from trading on the NEX and the
amalgamated entity will apply to cease being a reporting issuer under
the securities legislation of each province of Canada where it is a
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
Certain statements contained in this news release are forward-looking
and are subject to numerous risks and uncertainties, known and unknown.
For further information identifying known risks and uncertainties,
relating to financial resources, liquidity risk, volatility of share
price and other important factors that could cause actual results to
differ materially from those anticipated in the forward-looking
statements, please refer to the heading Risks and Uncertainties in
Warnex's most recent Management's Discussion and Analysis, which can be
found at www.sedar.com. Consequently, actual results may differ
materially from the anticipated results expressed in these
forward-looking statements. The Amalgamation is subject to the
satisfaction of the conditions under the Pre-Amalgamation Agreement.
There is no assurance that the Amalgamation will be completed as
proposed or at all. Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or accuracy
of this release.
SOURCE: Warnex Inc.
For further information:
Chairman of the Board of Directors, Warnex Inc.
Tel: (514) 940-3600